Kimonte-LC Tablet is a combination pharmaceutical formulation containing Levocetirizine 5 mg and Montelukast 10 mg, designed for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, rhinorrhea, and pruritus by blocking the action of histamine. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene receptor, preventing leukotriene-mediated bronchoconstriction, inflammation, and mucus secretion. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Kimonte-LC is indicated for patients requiring both antihistaminic and anti-leukotriene therapy, particularly in cases where monotherapy is insufficient. It is well-tolerated with a favorable safety profile; common adverse effects may include headache, fatigue, and gastrointestinal discomfort. The tablet should be administered orally once daily, preferably in the evening, with or without food. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with known hypersensitivity to any of the components. Kimonte-LC Tablet offers an effective therapeutic option for improved symptom control in allergic respiratory diseases.

Dosage & How to Use